Brain γ-aminobutyric acid abnormality in tardive dyskinesia: Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment

G. K. Thaker, C. A. Tamminga, L. D. Alphs, J. Lafferman, T. N. Ferraro, T. A. Hare

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

A double-blind, placebo-controlled trial of γ-vinyl γ-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP) was carried out in drug-free schizophrenic patients with tardive dyskinesia. A significant decrease in dyskinetic symptoms occurred with the administration of GVG, associated with a twofold increase in cerebrospinal fluid levels of GABA; THIP produced a more moderate, yet consistent decrease in the involuntary movements. A pathophysiologic role for γ-aminobutyric acid (GABA)-mediated neuronal transmission in tardive dyskinesia was explored by analyzing cerebrospinal fluid GABA concentrations in drug-free schizophrenic patients with and without tardive dyskinesia. A significant reduction in cerebrospinal fluid levels of GABA was observed in the dyskinetic schizophrenics compared with the nondyskinetic controls. These data complement a growing body of experimental evidence suggesting a critical role for GABA-ergic neurons in the pathophysiology of tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)522-529
Number of pages8
JournalArchives of General Psychiatry
Volume44
Issue number6
StatePublished - 1987

Fingerprint

GABA Agonists
Aminobutyrates
gamma-Aminobutyric Acid
Cerebrospinal Fluid
Brain
Therapeutics
GABAergic Neurons
Dyskinesias
Pharmaceutical Preparations
Placebos
Tardive Dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Brain γ-aminobutyric acid abnormality in tardive dyskinesia : Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. / Thaker, G. K.; Tamminga, C. A.; Alphs, L. D.; Lafferman, J.; Ferraro, T. N.; Hare, T. A.

In: Archives of General Psychiatry, Vol. 44, No. 6, 1987, p. 522-529.

Research output: Contribution to journalArticle

@article{1d8783c77d064ce4995c1cbfd80cb4f5,
title = "Brain γ-aminobutyric acid abnormality in tardive dyskinesia: Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment",
abstract = "A double-blind, placebo-controlled trial of γ-vinyl γ-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP) was carried out in drug-free schizophrenic patients with tardive dyskinesia. A significant decrease in dyskinetic symptoms occurred with the administration of GVG, associated with a twofold increase in cerebrospinal fluid levels of GABA; THIP produced a more moderate, yet consistent decrease in the involuntary movements. A pathophysiologic role for γ-aminobutyric acid (GABA)-mediated neuronal transmission in tardive dyskinesia was explored by analyzing cerebrospinal fluid GABA concentrations in drug-free schizophrenic patients with and without tardive dyskinesia. A significant reduction in cerebrospinal fluid levels of GABA was observed in the dyskinetic schizophrenics compared with the nondyskinetic controls. These data complement a growing body of experimental evidence suggesting a critical role for GABA-ergic neurons in the pathophysiology of tardive dyskinesia.",
author = "Thaker, {G. K.} and Tamminga, {C. A.} and Alphs, {L. D.} and J. Lafferman and Ferraro, {T. N.} and Hare, {T. A.}",
year = "1987",
language = "English (US)",
volume = "44",
pages = "522--529",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Brain γ-aminobutyric acid abnormality in tardive dyskinesia

T2 - Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment

AU - Thaker, G. K.

AU - Tamminga, C. A.

AU - Alphs, L. D.

AU - Lafferman, J.

AU - Ferraro, T. N.

AU - Hare, T. A.

PY - 1987

Y1 - 1987

N2 - A double-blind, placebo-controlled trial of γ-vinyl γ-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP) was carried out in drug-free schizophrenic patients with tardive dyskinesia. A significant decrease in dyskinetic symptoms occurred with the administration of GVG, associated with a twofold increase in cerebrospinal fluid levels of GABA; THIP produced a more moderate, yet consistent decrease in the involuntary movements. A pathophysiologic role for γ-aminobutyric acid (GABA)-mediated neuronal transmission in tardive dyskinesia was explored by analyzing cerebrospinal fluid GABA concentrations in drug-free schizophrenic patients with and without tardive dyskinesia. A significant reduction in cerebrospinal fluid levels of GABA was observed in the dyskinetic schizophrenics compared with the nondyskinetic controls. These data complement a growing body of experimental evidence suggesting a critical role for GABA-ergic neurons in the pathophysiology of tardive dyskinesia.

AB - A double-blind, placebo-controlled trial of γ-vinyl γ-aminobutyric acid (GVG) and 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridine-3-ol (THIP) was carried out in drug-free schizophrenic patients with tardive dyskinesia. A significant decrease in dyskinetic symptoms occurred with the administration of GVG, associated with a twofold increase in cerebrospinal fluid levels of GABA; THIP produced a more moderate, yet consistent decrease in the involuntary movements. A pathophysiologic role for γ-aminobutyric acid (GABA)-mediated neuronal transmission in tardive dyskinesia was explored by analyzing cerebrospinal fluid GABA concentrations in drug-free schizophrenic patients with and without tardive dyskinesia. A significant reduction in cerebrospinal fluid levels of GABA was observed in the dyskinetic schizophrenics compared with the nondyskinetic controls. These data complement a growing body of experimental evidence suggesting a critical role for GABA-ergic neurons in the pathophysiology of tardive dyskinesia.

UR - http://www.scopus.com/inward/record.url?scp=0023276203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023276203&partnerID=8YFLogxK

M3 - Article

C2 - 3034188

AN - SCOPUS:0023276203

VL - 44

SP - 522

EP - 529

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 6

ER -